Cutia Therapeutics Sets 2026 AGM to Vote on Board, Auditor and Share Mandates

Cutia Therapeutics ( (HK:2487) ) has provided an update.

Cutia Therapeutics has called its annual general meeting for 26 June 2026 in Shanghai, where shareholders will review the audited financial statements for the year ended 31 December 2025 and the accompanying reports from directors and auditors. The meeting will also vote on the re-election of several non-executive and independent non-executive directors, confirmation of directors’ remuneration, and the re-appointment of Ernst & Young as auditor.

Shareholders will further consider granting the board a general mandate to repurchase up to 10% of the company’s issued shares, in line with Hong Kong listing rules and subject to specified limits and timeframes. If approved, the mandates on share buy-backs and share issuance would give management greater flexibility in capital management and corporate actions over the coming year, potentially influencing liquidity, ownership structure and future financing strategies.

More about Cutia Therapeutics

Cutia Therapeutics, incorporated in the Cayman Islands and listed in Hong Kong under stock code 2487, operates in the biopharmaceutical and therapeutics sector. The company focuses on developing and commercializing healthcare treatments, with its governance and financial reporting aligned to Hong Kong listing requirements and international auditing standards.

Average Trading Volume: 270,682

Technical Sentiment Signal: Sell

Current Market Cap: HK$1.71B

For a thorough assessment of 2487 stock, go to TipRanks’ Stock Analysis page.